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There is persuasive epidemiological and experimental evi-
dence that dietary polyphenols have anti-inflammatory activity.
Aspirin and other non-steroidal anti-inflammatory drugs
(NSAIDs) have long been used to combat inflammation. Re-
cently, cyclooxygenase (COX) inhibitors have been developed
and recommended for treatment of rheumatoid arthritis (RA)
and osteoarthritis (OA). However, two COX inhibitors have
been withdrawn from the market due to unexpected side effects.
Because conventional therapeutic and surgical approaches have
not been able to fully control the incidence and outcome of
many inflammatory diseases, there is an urgent need to find
safer compounds and to develop mechanism-based approaches
for the management of these diseases. Polyphenols are found
in many dietary plant products, including fruits, vegetables,
beverages, herbs, and spices. Several of these compounds have
been found to inhibit the inflammation process as well as
tumorigenesis in experimental animals; they can also exhibit
potent biological properties. In addition, epidemiological
studies have indicated that populations who consume foods rich
in specific polyphenols have lower incidences of inflammatory
disease. This paper provides an overview of the research
approaches that can be used to unravel the biology and health
effects of polyphenols. Polyphenols have diverse biological
effects, however, this review will focus on some of the pivotal
molecular targets that directly affect the inflammation process.
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INTRODUCTION
Inflammation is the immunological defense
mechanism by which the body fights infection or
injury from bacteria, viruses and other pathogens.
The defining clinical features of inflammation are
known in Latin as rubor (redness), calor (warmth),
tumor (swelling) and dolor (pain). These hall-
marks of inflammation were first described by
Aurelius Cornelius, a Roman physician and medi-
cal writer who lived from about 30 B.C. to 45 A.D.
The redness and swelling that occurs at the site
of a wound is due to the widening blood vessels
to allow specialized white blood cells to enter and
battle the pathogens. Following this process, the
inflammation fades and healing begins. Excessive
or inadequate activation of the system can have
serious effects, as can the failure of the inactiva-
tion mechanism. In the early 1970s, aspirin and
other non-steroidal anti-inflammatory drugs
(NSAIDs) were found to inhibit cyclooxygenase
(COX), which produces prostaglandins (PGs), a
class of physiological and pathophysiological inflam-
matory mediators.
1 Since then, the biosynthetic
cascade of arachidonic acid (AA) has been the
subject of intense research. This is because AA,
having been previously liberated from phospho-
lipids using various stimuli, can be metabolized
by the COX pathway into PGs and thromboxane
A2, or by the lipoxygenase (LOX) pathways to
hydroperoxyeicosateraenoic acids (HpETEs), hydro-
xyeicosateraenoic acids (HETEs) and leukotrienes
(LTs) (Fig. 1). These two proteins play a vital role
in inflammation by controlling the intensity and
duration of pain, as well as the occurrence of
fever, swelling and heat of an affected area. Al-
though steroidal anti-inflammatory drugs and
NSAIDs are currently used to treat acute inflam-
mation, these drugs have not been successful in
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curing chronic inflammatory diseases, such as
bronchiectasis, rheumatoid arthritis (RA), osteo-
arthritis (OA), and inflammatory bowel disease
(ulcerative colitis and Crohn's disease). Recently,
Vioxx and Celebrex, two blockbuster drugs used
to treat arthritis, were withdrawn from the drug
market due to their cardiovascular side effects.
These cases provide examples of the unknown
side effects produced by synthetic drugs, and
suggest that an evaluation of the long-term effects
of drugs may be required.
Alternatively, a large number of dietary poly-
phenols have been consumed in food, and their
anti-inflammatory activities have been reported.
Polyphenols can be classified into four different
groups: flavonoids, stillbenes, lignas, and phe-
nolic acids (Fig. 2). These compounds have
received considerable attention from the public.
Fig. 1. Arachidonic acid (AA)
pathways. AA can be converted
to either prostaglandins or
leukotrienes, depending on the
enzymes that are present. Each
metabolite affects its biological
action through receptors.
Fig. 2. The structure of four
major polyphenols found in the
diet.Molecular Targets of Dietary Polyphenols with Anti-inflammatory Properties
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In fact, 12 out of the 40 anti-inflammatory drugs
approved between 1983 and 1994 were derived
from or based on these natural products.
2 These
molecules are secondary metabolites of plants
and are generally involved in the defense mech-
anism against ultraviolet radiation and insects.
Some of the polyphenols found to be beneficial to
health were characterized as naturally-occurring
toxicants in plants. In excess, some polyphenols
resulted in growth depression in poultry,
livestock and laboratory animals. However, the
intake of small amounts of polyphenols in food
has a potent effect on reducing chronic diseases
in animal models. Epidemiological studies have
indicated that populations who consume foods
rich in specific polyphenols have a lower
incidence of chronic inflammatory diseases.
Kuhnau et al. calculated that dietary polyphenol
intake in the US was ~1 g/day.
3 Some studies
have subsequently provided more precise in-
dividual data regarding the intake of various
classes of dietary polyphenols. Flavonols (one of
the flavonoids) have been more extensively
studied, and the consumption of these substances
has been estimated at 20-25 mg/day in the US.
4
The plasma concentrations of flavonoids are
usually <10 μM and the steady-state levels are
typically <1 μM.
5 However, the concentrations of
total polyphenols may be higher than those of
flavonoids.
We have been studying the effects of several
dietary polyphenol compounds (including resve-
ratrol, genistein, catechin, and indole-3-carbinol)
on chronic diseases in humans, such as inflam-
mation and cancer.
6-9 The potential molecular
mechanisms of their anti-inflammatory activities
have also been suggested to include, but not
limited to, the inhibition of enzymes related to in-
flammation, such as cyclooxygenase and lipoxy-
genase, and many others including PPAR, NOS,
NF-κB, and NAG-1. Thus, polyphenols can in-
fluence many pathways, and other compounds
may also affect the same pathways. The detailed
mechanisms by which each polyphenol induces
anti-inflammation remain to be elucidated. In this
review, we summarized the current findings of
the molecular targets of polyphenols as anti-in-
flammatory compounds. We focused on two mo-
lecular aspects: the arachidonic acid (AA)-depen-
dent pathway and the AA-independent pathway.
Cyclooxygenase, lipoxygenase, and PLA2 are dis-
cussed as AA-dependent pathway proteins by
polyphenols, whereas NOS, NF-κB, PPAR, and
NAG-1 are discussed as AA-independent pathway
proteins. There is great potential for dietary poly-
phenols to become the next generation of dietary
factors to confer health effects for inflammation
beyond synthetic drugs. Further, dietary poly-
phenols may provide an excellent model system
for the development of more effective drugs in the
future.
ARACHIDONIC ACID DEPENDENT PATHWAY
COX inhibition
An anti-inflammatory effect is believed to result
from inhibiting the formation of prostaglandins by
prostaglandin H synthase (COX, also called
cyclooxygenase), which converts arachidonic acid
(AA) released by membrane phospholipids into
prostaglandins. Two isoforms of prostaglandin H
synthase, COX-1 and COX-2, have been identified,
and one variant form (COX-3) has recently been
reported as well.
10 COX-1 is constitutively ex-
pressed in many tissues, while the expression of
COX-2 is regulated by mitogens, tumor promo-
ters, and growth factors.
11 NSAIDs are widely
used in the treatment of inflammatory diseases.
Since aspirin was synthesized, a number of as-
pirin-like drugs have also been developed. As-
pirin and other NSAIDs (also known as conven-
tional NSAIDs that block COX-1 and COX-2)
induce gastric ulcerization and kidney failure due
to COX-1 inhibition. COX-1 is necessary for the
protection of the stomach lining, so interfering
with its activity can cause gastrointestinal distur-
bances ranging from simple discomfort to
bleeding ulcers. This hypothesis was confirmed
when newly developed drugs that specifically in-
hibited COX-2 were shown to have a lower rate
of gastrointestinal bleeding when compared to
conventional NSAIDs.
12 However, the “good” COX-1
versus “bad” COX-2 dichotomy has proven overly
simplistic. COX-2 has been shown to exert normal
physiological effects, including the regulation of
vascular and renal blood flows.
13 The identifica-Joo-Heon Yoon and Seung Joon Baek
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tion of COX-2 was not expected to increase the
effectiveness of NSAID therapy, since conven-
tional NSAIDs inhibited both COX-1 and COX-2.
However, the identification of cyclooxygenase 3
(COX-3) may contribute to the elucidation of the
inflammatory process.
10 COX-3 has also raised
many questions by researchers studying the ef-
fects of acetaminophen. The weak level of COX-3
inhibition induced by acetaminophen probably
does not occur with standard oral dosages of acet-
aminophen (0.5-1 g/day). Thus, other hypotheses
regarding acetaminophen's mechanisms of action
should be considered. Although the marketing of
new COX-2 inhibitors has emphasized the advan-
tages of not blocking the necessary COX-1 path-
way, infrequent reports of gastrointestinal pro-
blems still exist from the use of these medications.
Both Celebrex and Vioxx were withdrawn from
the market in 2005 due to an increase in cardio-
vascular risks, likely caused by the thromboxane
formed via the COX-1 pathway.
14 Therefore, a
clinical trial that involves patients switching from
one synthetic agent to a different agent could be
valuable. Several compounds that are consumed
daily in various foods may provide alternative
tools for treating inflammatory diseases by acting
as COX inhibitors.
In 1980, Baumann et al. were the first to report,
in a study that assessed rat medullar COX
activity, that some dietary polyphenols, such as
galangin and luteolin, inhibit AA peroxidation.
15
Since then, several researchers have reported that
many dietary polyphenols inhibit COX activity at
the transcriptional level as well as at the enzyme
level. For instance, Landolfi et al. found that fla-
vone, chrysin, apigenein, and phloretin depressed
COX activity and inhibited platelet aggregation.
16
The flavonoids, 6-hydroxykaempferol, and quer-
cetagenin isolated from T. parthenium (feverfew),
and 6-hydroxyluteolin and scutellarein isolated
from T. vulgaris (tansy) were shown to inhibit
COX activity in leukocytes.
17 The triterpenes
sasanquol isolated from C. sasanqua (Theaceae)
and 3β-p-hydroxybenzoyldehydrotumulosic acid
from the fungus P. cocos (Polyporaceae) produced
activity against 12-O-tetradecanoylphobol-13-acetate
(TPA) and also AA-induced ear inflammation in
mice,
18 which was probably caused by the COX-
2 inhibition. Pre-treatment with green tea extract
enriched with catechin and epigallocatechin gal-
late (EGCG) by gavage inhibited COX-2 expres-
sion that was induced by the tumor promoter
12-O-tetradecanoylphorbol-13-acetate (TPA) in
mouse skin. Similarly, EGCG down-regulated
COX-2 in TPA-stimulated human mammary
epithelial cells (MCF-10A) in culture.
19 Both the
green tea catechin and the EGCG displayed COX
inhibition activity in LPS-induced macrophages
20
and inhibited IL-1β-dependent pro-inflammatory
signal transduction in cultured respiratory epi-
thelial cells.
21 The stillbene compound resveratol
possesses anti-inflammatory activity because it
suppresses carragenen-induced pedal edema via
the inhibition of COX activity.
22 Furthermore,
resveratrol inhibits TPA-induced COX-2 expres-
sion at the transcriptional level.
23 Thus, the mecha-
nism by which resveratrol exerts anti-inflam-
matory activity may be related to the inhibition of
either COX transcription or COX activity. Studies
using isolated bovine COX-1 and COX-2 enzymes
showed that curcumin had significantly higher
inhibitory effects on the peroxidase activity of
COX-1 than that of COX-2.
24 EGCG and resve-
ratrol were the most effective COX-1 inhibitors
among those tested in the study.
20 Genistein
down-regulates COX-2 promoter activity in colon
cancer cells transfected with a COX-2 reporter
gene system.
25 Wogonin and sophoraflavanone-G
down-regulate COX-2 expression from TNF-α
treated NIH/3T3 cells and LPS treated RAW cells,
respectively. This suggests that the COX-2 down-
regulation of skin fibroblasts may in part be one
of the anti-inflammatory mechanisms these
compounds exert against skin inflammation such
as atopic dermatitis.
26,27 Although many studies
have reported that polyphenols inhibit COX-1 or
COX-2, it has not yet been reported that
polyphenols inhibit COX-3. Collectively, several
polyphenols were reported to have anti-inflam-
matory effects, as assessed by COX inhibition.
COX inhibition by polyphenols may account for
these anti-inflammatory effects, which reduce
prostaglandin synthesis. Therefore, it should be
noted that the concurrent use of polyphenols and
NSAIDs could be beneficial or deleterious, and
thus necessitates constant attention by healthcare
providers.Molecular Targets of Dietary Polyphenols with Anti-inflammatory Properties
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LOX inhibition
LOXs are the enzymes responsible for gene-
rating hydroxyl acids and leukotrienes (LTs) from
AA (Fig. 1). There are three distinct LOX isozymes
in that affect different cells and tissues. 15-LOX
synthesizes anti-inflammatory 15-HETE, 5; 12-LOX
is involved in provoking inflammatory/allergic
disorders; and 5-LOX produces 5-HETE and LTs,
which are potent chemoattractants and lead to the
development of asthma. 12-LOX synthesizes 12-
HETE, which aggregates platelets and induces the
inflammatory response. Therefore, the effect of
polyphenols on 5- and 12-LOXs has been exten-
sively studied in order to elucidate the anti-in-
flammatory properties. Flavonols, including
kaempferol, quercetin, morin and myricetin, were
found to be 5-LOX inhibitors.
28 With IC50 values
ranging from 1.0 to 18.7 M, hamamelitannin and μ
the galloylated proanthocyanidins were found to
be the most potent inhibitors of 5-LOX.
29 Some
prenylated flavonoids, such as artonin E, are the
most effective inhibitors of porcine leukocyte 5-
LOX.
30 An anti-inflammatory neolignan sibyllen-
one from Ocotea bullata (black stinkwood) was also
active against 5-LOX.
31 Baicalein was reported to
selectively inhibit platelet 5-LOX.
32 Curcumin
blocks the activity of human recombinant 5-LOX.
24
In contrast, there are few reports regarding 12-
LOX inhibition. Using bovine PMNs and 12-LOX
from bovine platelets, kuwanson C and quercetin
potently inhibit 12-LOX activity,
33 with IC50 values
of 19 and 12 M, respectively. In comparison, the μ
IC50 value of the known LOX inhibitor nordihy-
droguaiaretic acid (NDGA) is 2.6 M. μ
COX and LOX inhibitions
The LOX pathway produces leukotrienes. When
only COX-2 is blocked, the LOX pathway still
produces the potent mediators of inflammation.
The condition may even be exacerbated by
blocking only the inflammatory cascade of COX-2,
which allows the LOX branch to accelerate the
formation of leukotrienes. Dual inhibition of
LOX/COX has been suggested to be a desirable
approach in the development of new drugs for
anti-inflammation.
34 Thus far, researchers have
not been able to bypass certain limiting barriers to
produce such a medication. This is important
since some researchers have found that COX-2
inhibition alone will exacerbate the production of
pro-inflammatory cytokines such as TNF-α and
IL-1β, both of which cause destructive damage to
inflammatory sites. Hong et al. demonstrated that
curcumin fits in this category of agents.
24 Many
other polyphenols are also the inhibitors of both
COX and LOX. Subsequently, a general structure
rule has been found: more COX inhibitions and
less LOX inhibitions with polyphenols contain few
hydroxyl substituents.
35
PLA2 inhibition
Phospholipase A2 (PLA2), the enzyme that
cleaves phospholipids producing lysophospho-
lipids and free fatty acids, was originally iden-
tified as an intracellular protein involved in cell
signaling and in the production of free fatty acids,
such as arachidonic acid.
36 It is known that PLA2
plays an important role in the inflammation pro-
cess. The inhibition of PLA2 could be a potential
therapeutic agent for curing human inflammatory
diseases (Fig. 1). Phospholipases are mainly clas-
sified into three large groups: secretory PLA2
(sPLA2), cytosolic PLA2 (cPLA2), and calcium-in-
dependent PLA2 (iPLA2). It is now known that
this family is comprised of at least 10 members
with distinct cellular distributions and growing
therapeutic potential.
37 Specifically, sPLA2-V and
sPLA2-X are selectively expressed in the epithe-
lium of the human airway. sPLA2-IIA is low but
becomes highly expressed during inflammation
and sepsis as a result of LPS, cytokine and NF-κB
induction. This enzyme is now associated with
allergic rhinitis, rheumatoid arthritis, and septic
shock. Finally, the selective expression of sPLA2-V
and sPLA2-X suggests that these enzymes should
be evaluated as targets for airway dysfunction.
Thus, the PLA2 family represents a therapeutic
target with ever-increasing potential. It is likely
that PLA2 is an important intra- and extracellular
mediator of inflammation. The modulation of
sPLA2 and/or cPLA2 activity is important in con-
trolling the inflammatory process.
Quercetin was found to be an effective inhibitor
of PLA2 in human
38 and rabbit
39 leukocytes. It was
also demonstrated that quercetin selectively inhi-Joo-Heon Yoon and Seung Joon Baek
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bited sPLA2-II, compared to its lower inhibition of
sPLA2-IB.
40 Quercetagetin, kaempferol-3-O-galac-
toside, and scutellarein inhibited human recom-
binant synovial PLA2 with IC50 values ranging
from 12.2 to 17.6 M. μ
41 Morelloflavone inhibited
sPLA2 with its selectivity for Group II and III
enzymes in vitro, including a high potency for the
human recombinant synovial PLA2.
42 Curcumin
affects AA metabolism by blocking the phospho-
rylation of cPLA2, resulting in decreased COX-2
expression.
24 Since PLA2 is coupled with COXs
and LOXs (depending on the cells), the inhibitors
of PLA2 may also cause the inhibition of COX or
LOX activity. PLA2 inhibition of some poly-
phenols may contribute to their anti-inflammatory
property in vivo as well.
43
AA-INDEPENDENT PATHWAY
Peroxisome proliferator activated receptors
(PPARs)
Many inflammatory cytokines are produced
and regulated at the transcriptional level, which
can either enhance or inhibit the inflammation
process. One such molecular link between pro-
inflammatory cytokines and transcription factor is
peroxisome proliferator-activated receptors (PPARs).
PPARs are nuclear hormone receptors that are
activated by specific endogenous and exogenous
ligands.
44 Three isoforms (α, / βδ, and γ) have been
identified and are encoded by separate genes.
Among those, PPAR activation is responsible for α
the pleiotropic effects of peroxisome proliferators,
such as enzyme induction, peroxisome
proliferation, liver enlargement and anti-inflam-
mation.
45 PPAR also plays a critical role in the α
regulation of cellular uptake and β-oxidation of
fatty acids.
46 In contrast, PPARδ (also known as
PPARβ) is widely expressed with relatively higher
levels in the brain, colon, and skin. Although
there have been extensive studies on PPAR and α
inflammation, very little is known about the effect
of PPARδon inflammation. In contrast, PPARγ has
been further divided into three subtypes: PPARγ1,
γ2, and γ3.
47,48 All PPAR isotypes form a
heterodimeric complex with the retinoid X
receptor (RXR), and the complex binds to the
PPAR response element (PPRE), which functions
as the central regulator of cellular differen-
tiation,
49 apoptosis,
50,51 inflammatory responses,
52,53
lipid metabolism and metabolic disease.
54 The first
study that provided evidence of a potential role
for PPARs in the inflammatory response showed
that the duration of the inflammatory response is
prolonged in PPARα-KO mice in response to
LTB4.
55 Since then, a growing body of evidence
has suggested that PPAR ligands inhibit pro-in-
flammatory cytokines in monocytes.
52 Thus, the
activation of PPAR results in anti-inflammatory
activity.
Genistein increased the expression of genes
involved in lipid catabolism; this effect is not
estrogen receptor-dependent, but instead is PPAR
-dependent. α
56 EGCG also binds to PPARα.
57
Amentoflavone up-regulates PPAR γ expression in
A549 human lung epithelial cells.
58 Few studies
have regarded polyphenols as PPAR ligands, but
it is probable that polyphenols may also affect
PPAR protein expression, which results in the
activation of the PPAR pathway. It is notable that
the PPAR pathways are tightly connected to other
inflammatory pathways including NF-κB, COX-2
expression, and pro-inflammatory cytokines. These
results demonstrate that the activation of PPARs
by certain polyphenols represent another possi-
bility the treatment of chronic inflammatory
diseases.
Nitric oxide synthase (NOS)
Nitric oxide (NO), a gaseous free radical, is
released by a family of enzymes, including endo-
thelia NOS (eNOS), neuronal NOS (nNOS) and
inducible NOS (iNOS), with the formation of stoi-
chiometric amounts of L-citrulline from L-arginine.
59
Excessive and prolonged iNOS-mediated NO
generation has attracted attention because of its
relevance to inflammation. Since NO is one of the
inflammatory mediators, the inhibition of NO by
the extracts of edible plants has been reported.
60
Using LPS/cytokine-treated macrophages or macro-
phage-like cell lines, quercetin was found to in-
hibit the production of NO.
61 However, mecha-
nism studies have shown that compounds down-
regulate iNOS expression, which subsequently
results in reducing the amount of NO production.Molecular Targets of Dietary Polyphenols with Anti-inflammatory Properties
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Several flavonoid derivatives, including apigenin,
quercetin, and morin, have also inhibited NO
production from LPS/interferonγ-activated C6
astrocytes.
62 Quercetin markedly inhibits the pro-
duction of TNF-α and NO by LPS-activated macro-
phages, and TNF- inhibition may occur post- α
transcriptionally, whereas iNOS inhibition usually
occurs at the transcriptional level.
63 Many poly-
phenols, including 6-gingerol,
64 EGCG,
65 resvera-
trol,
66 indole-3-carbinol,
67 and oroxylin A,
68 inhibit
NOS expression in LPS-induced RAW264.7 cells.
These effects are probably mediated by NF-κB
inhibition.
69
NF- B κ
Nuclear transcription factor κB (NF-κB), which
was discovered by David Baltimore in 1986, is a
ubiquitous factor that resides in the cytoplasm.
When it becomes activated, it is translocated to
the nucleus, where it induces gene transcription.
NF-κB is activated by free radicals, inflammatory
stimuli, carcinogens, tumor promoters, endotox-
ins, γ-radiation, ultraviolet (UV) light, and X-rays.
Upon activation, NF-κB induces the expression of
more than 200 genes that have been shown to
suppress apoptosis and induce cellular transfor-
mation, proliferation, invasion, metastasis, chemo-
resistance, radio-resistance, and inflammation. The
activated form of NF-κB has been found to medi-
ate cancer, atherosclerosis, myocardial infarction,
diabetes, allergy, asthma, arthritis, and other in-
flammatory diseases. It is not surprising that NF-κ
B has been linked to this wide variety of diseases,
because most diseases are caused by poorly re-
gulated inflammation. Therefore, agents that can
suppress NF-κB activation, in principle, have the
potential to prevent, delay the onset of, or treat
inflammatory diseases.
Several sesquiterpene lactones demonstrated
anti-inflammatory properties by inhibiting the
binding of the transcription factor NF-κB, as as-
sessed by a gel shift assay.
70 Quercetin was re-
ported to suppress TNF- induced expression of α
IL-8 and monocyte chemoattractant protein (MCP-
1) due to its ability to inhibit the activation of NF-
κB.
71 Quercetin also inhibited the NF-κB pathway
without any modification of c-Jun N- terminal
kinase activity both in vivo and in vitro.
72 Caffeic
acid phenethyl ester (CAFE), a natural product
secreted by the honeybee, inhibited cerebral in-
flammatory responses by reducing the activity of
NF-κB.
73 Resveratrol has also been known to
inhibit NF-κB activity, although resveratrol may
possess anti-inflammatory properties via an NF-κ
B-independent mechanism.
74 Recently, it has been
reported that indole-3-carbinol, found in Brassica
sp. vegetables (such as cabbage, cauliflower, and
brussel spouts), inhibits NF-κB and NF-κB-re-
gulated gene expression.
75 The inhibition of NF-κB
by several polyphenols may explain the anti-
inflammatory effects of these compounds.
NAG-1
NAG-1 (NSAID activated gene-1) was identified
by PCR-based subtractive hybridization from an
NSAID-induced library in cyclooxygenase-nega-
tive cells as a divergent member of the TGF-β
superfamily.
76 The induction of NAG-1 by NSAIDs
is an important COX-independent mechanism by
which some of these proven anti-inflammatory
compounds mediate their effects.
77 NAG-1 has
been identified by other groups, as macrophage
inhibitory cytokine-1 (MIC-1),
78 placental transfor-
mation growth factor- (PTGFB), β
79 prostate de-
rived factor (PDF),
80 growth differentiation factor
15 (GDF-15),
81 and placental bone morphogenetic
protein (PLAB).
82 The diversity of biological func-
tions represented by this nomenclature suggests
that the NAG-1 protein has broad activity in in-
flammation, cancer, and differentiation. The mole-
cular mechanisms responsible for these functions
have yet to be determined in detail. Experimental
evidence suggests that NAG-1 may share at least
some of the common functions of TGF-β super-
family cytokines. For instance, TGF-β1 induces
apoptosis and cell growth arrest in epithelial cells,
and mice treated with TGF-β1 died of widespread
inflammation. Indeed, NAG-1 expression reduces
TNF-α secretion in macrophages,
78 and inhibits the
proliferation of primitive hemopoietic progeni-
tors
83 and several epithelial cancer cell
lines,
76,77,79,84,85 reflecting the activity of a multi-
functional cytokine. In contrast to other members
of the TGF- superfamily, NAG-1 is induced not β
only by several NSAIDs, but also by several die-
tary compounds. As described in Table 1, NAG-1Joo-Heon Yoon and Seung Joon Baek
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was initiated by many of the polyphenols de-
scribed in this review. All of the listed compounds
induced NAG-1 expression, except EC and EGC,
which indicates the structure-specific expression
of NAG-1 induction. Overall, NAG-1 could prove
to be a good molecular target protein for examin-
ing the anti-inflammatory and/or anti-cancer ac-
tivity of other compounds.
CONCLUSION
Dietary polyphenols comprise a vast array of
biologically active compounds that are ubiquitous
in plants, many of which have been used in
traditional Oriental medicine for thousands of
years. In this review, we summarized the different
targets of dietary polyphenols by their anti-in-
flammatory effects. Given that certain polyphenols
are known to affect more than one protein, it is
necessary consider possibility that any single com-
pound may affect multiple mechanisms. However,
most of the previous clinical studies have used
foods or beverages containing a mixture of dif-
ferent polyphenols, and the exact mechanisms of
the most active polyphenol components remain
largely unknown. Therefore, these factors should
be taken into consideration along with bioavail-
ability in order to improve the experimental
design and interpret the observed effects. In addi-
tion, since absorption, metabolism, and elimina-
tion vary widely among polyphenols, these factors
should also be considered Furthermore, such char-
acterization of these compounds could validate
the importance of dietary polyphenol compounds
in human health and encourage their use as
templates for further structural development of
more effective and safe chemopreventive com-
pounds.
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